

PhytoCell Biotech

Investor Brief 2026

PhytoCell Biotech is a Manhattan-based biotechnology company building a synthetic biology and precision fermentation platform for the production of high-purity cannabinoids, starting with CBD and extending toward future differentiated cannabinoid ingredients.

Founded	2018
Headquarters	Manhattan, New York
Core Platform	Synthetic biology + engineered microbial cell factories + precision fermentation
Primary Opportunity	Scalable, traceable cannabinoid production with stronger quality consistency
Commercial Pathways	Ingredient supply, co-development, formulation partnerships, licensing

Investment Highlights

- Differentiated biosynthetic platform focused on consistent cannabinoid production.
- Precision fermentation model designed for scalable manufacturing and stronger process control.
- Value creation across strain engineering, pathway design, bioprocess development and downstream purification.
- Partner-ready operating structure supporting research, manufacturing and commercial collaboration.
- Long-term roadmap extending beyond CBD toward future cannabinoid products and formulations.

Corporate Contact

Investor Relations: investors@phytoCELLbiotech.com
General Inquiries: info@phytoCELLbiotech.com